Clinical Trial Update: A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Regeneron is conducting a Phase 1/2 clinical trial to evaluate REGN4336 alone and in combination with cemiplimab or REGN5678 for adults with metastatic castrati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• REGN4336
• REGN5678

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING